Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations

Completed · Phase 4 · Has a placebo group

Conditions studied: Erythromelalgia

In brief

This research study is designed to investigate brain response using fMRI scan, and behavioral responses, to treatment with the drug carbamazepine (CBZ) in patients with the painful sodium channelopathy inherited Erythromelalgia (IEM). This study is designed to identify the central nervous system (CNS) regions that are activated during ongoing or evoked pain attacks, and the altered CNS response to CBZ treatment. This will advance our understanding of how IEM affects the brain. We also hope to validate a pharmacogenic approach to the study of IEM by use of an FDA approved drug. We hope, but cannot be sure, that subjects will directly benefit from this study.

Key facts

Study ID

NCT02214615

Run by

VA Connecticut Healthcare System

People needed

2

Starts

2014-04-01

Expected to finish

2016-07-01

Last updated by the study team

2017-06-06

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• diagnosis/symptoms of EM
• specific NaV1.7 sodium channel mutations (including S241T)

You may not qualify if…

• patients with no identified NaV1.7 mutation

Where it is running

• Yale University — New Haven, Connecticut, United States
• VA Connecticut Healthcare System — West Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.